A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT versus TKI, blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab in suboptimal responders (GMALL-EVOLVE)

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2023
This article has no abstract
Epistemonikos ID: 4578bb3369ed713a17b5d7e2f8deb1d370409ef7
First added on: Apr 17, 2025